EMA CHMP has recommended the following for approval: Fylrevy, Ilumira, Kayshild, Kygevvi, Supemtek & Rezurock.

• Recommended an extension on Zynyz. Positive option to extend Eurneffy. and seven other extensions for: Akeega, Efmody, Iclusig, Imfinzi, Kerendia, Noxafil and Opdivo.

The EMA's recommendation for the approval of multiple drugs, including Fylrevy and Ilumira, signals potential growth opportunities for Sanofi and other pharmaceutical companies involved, underscoring the regulatory momentum in the sector. This could lead to positive sentiment in equities within the biotechnology and life sciences space, particularly as investors assess the implications for future revenues and competitive positioning.